NASDAQ: CNTXContext Therapeutics Inc Stock
$0.88+0.04 (+4.76%)
Updated May 26, 2023
CNTX Price
$0.88
Fair Value Price
N/A
Market Cap
$14.05M
52 Week Low
$0.47
52 Week High
$2.52
P/E
-0.79x
P/B
0.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$15M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTX Overview
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer treatments for women. Candidates include ONA-XR (onapristone extended release) to treat female hormone-dependent cancers, and CLDN6xCD3 bsAb, intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6 (Claudin 6). The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, PA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNTX is good value based on its book value relative to its share price (0.49x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
CNTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CNTX due diligence checks available for Premium users.
Be the first to know about important CNTX news, forecast changes, insider trades & much more!
CNTX News
Valuation
CNTX fair value
Fair Value of CNTX stock based on Discounted Cash Flow (DCF)
Price
$0.88
Fair Value
$3.25
Undervalued by
72.94%
CNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.79x
Industry
11.86x
Market
54.23x
CNTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
5.18x
CNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
CNTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$32.0M
Liabilities
$3.2M
Debt to equity
0.11
CNTX's short-term assets ($31.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTX's short-term assets ($31.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
$0.0
Financing
$0.0
CNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTX vs Biotech Stocks
Context Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.